Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director · President and CEO | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,133,777 |
Reported balance
After 2026-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-16 · Exercise / conversion · Acquired 15,000 · Balance 2,133,777 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 2,118,777 |
Reported balance
After 2026-03-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-16 · Sale · Disposed 15,000 · Balance 2,118,777 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. F2: The price reported in Column 4 is the price at which the shares were sold. |
| Common StockSEC Table I · non-derivative | Direct | 2,112,777 |
Reported balance
After 2026-03-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-03-16 · Sale · Disposed 6,000 · Balance 2,112,777 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. F2: The price reported in Column 4 is the price at which the shares were sold. F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2034-02-26 | Direct | 690,950 |
Reported balance
After 2026-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-16 · Exercise / conversion · Disposed 15,000 · Balance 690,950 F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,143,426 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,143,426 F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 580,957 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 580,957 F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
F2: The price reported in Column 4 is the price at which the shares were sold.
F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 1,589,987 | $4.61 | $7,329,840.07 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 8 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,523,088 Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 510,469 | $4.54 | $2,318,958.57 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 7 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,113,075 F1 · price: Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.495 to $4.63, inclusive. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 583,224 | $3.66 | $2,134,599.84 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 6 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,623,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 350,000 | $3.71 | $1,298,500.00 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 5 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,040,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 400,000 | $3.22 | $1,288,000.00 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 4 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,690,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 277,604 | $2.92 | $809,215.66 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 3 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,290,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 277,131 | $2.35 | $651,257.85 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,012,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 212,500 | $1.67 | $354,875.00 |
DisclosureSEC source: 0001140361-23-040322 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,735,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 20,051 | $3.69 | $73,988.19 |
DisclosureSEC source: 0001140361-23-033190 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,523,085 F1 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 340,313 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,254,736 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 01:06 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 17,853 | $3.31 | $59,093.43 |
DisclosureSEC source: 0001140361-23-016458 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,543,139 F1 · balance_after: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 397,032 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,218,071 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 23,607 | $3.40 | $80,263.80 |
DisclosureSEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 5 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,560,992 F2 · balance_after: (continued from footnote 1) (iv) 104,341 unvested RSUs granted on February 25, 2021, of which 91,575 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 12,766 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (v) 25,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 1,179,206 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. F4 · balance_after: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 1,147,385 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-23-010774 · form4.xml · derivative · entry 8 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147,385 Underlying: Common Stock · 1,147,385 shares Expires 2033-03-06 F6 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 573,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 4 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,584,599 F1 · shares: Includes, as of the transaction date, (i) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 453,750 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; Read SEC document |
| February 28, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 7,507 | $3.55 | $26,649.85 |
DisclosureSEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 3 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010,904 Read SEC document |
| February 25, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 14,412 | $3.42 | $49,289.04 |
DisclosureSEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,018,411 Read SEC document |
| February 25, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 4,018 | $3.42 | $13,741.56 |
DisclosureSEC source: 0001140361-23-010774 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,032,823 Read SEC document |
| January 04, 2023 Filed Jan 7, 2023 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 166,867 | $3.87 | $645,775.29 |
DisclosureSEC source: 0001140361-23-000873 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036,841 F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 453,750 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; F2 · balance_after: (continued from footnote 1) (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 1,070,198 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| December 09, 2022 Filed Dec 9, 2022 21:41 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 14,982 | $2.86 | $42,848.52 |
DisclosureSEC source: 0001140361-22-045111 · form4.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,143,426 F1 · shares: Represents a purchase from the underwriters in the December 2022 public offering of the issuer. F5 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| December 09, 2022 Filed Dec 9, 2022 21:41 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 14,983 | $2.86 | $42,851.38 |
DisclosureSEC source: 0001140361-22-045111 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,203,708 F1 · shares: Represents a purchase from the underwriters in the December 2022 public offering of the issuer. F2 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (continued) F3 · balance_after: (continued from prior footnote) (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (continued) F4 · balance_after: (continued from prior footnote) (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 783,315 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:21 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 101,315 | $2.43 | $246,195.45 |
DisclosureSEC source: 0001140361-22-036164 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,188,725 F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's (continued) F2 · balance_after: (continued from prior footnote) continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 768,332 shares of common stock owned by the reporting person, which reflects previous purchases and prior net settlements upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| May 11, 2022 Filed May 14, 2022 01:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 70,004 | $1.43 | $100,105.72 |
DisclosureSEC source: 0001140361-22-019215 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,290,040 F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 330,412 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the F2 · balance_after: (continued from footnote 1) Compensation Committee of the Board of Directors, which shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's F3 · balance_after: (continued from footnote 2) continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 539,234 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:15 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 50,539 | $1.46 | $73,786.94 |
DisclosureSEC source: 0001140361-22-011249 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,360,044 F1 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 577,665 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the F2 · balance_after: (continued from footnote 1) Compensation Committee of the Board of Directors, of which (x) 247,253 of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (y) 330,412 of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting F3 · balance_after: (continued from footnote 2) 2. person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 361,986 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:58 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001140361-22-008671 · form4.xml · derivative · entry 4 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2032-03-07 F8 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:58 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-008671 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,410,583 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes (i) 300,000 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 907,500 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; F3 · balance_after: (continue from footnote 2) (iii) 742,500 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, F4 · balance_after: (continue from footnote 3) subject to the reporting person's continued employment on the applicable vesting date; (iv) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; F5 · balance_after: (continue from footnote 4) (v) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 247,690 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 11:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 250,000 | $1.00 | $250,000.00 |
DisclosureSEC source: 0001140361-21-035379 · form4.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,128,444 F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer. F6 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 11:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 100,000 | $1.00 | $100,000.00 |
DisclosureSEC source: 0001140361-21-035379 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,137,616 F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer. F2 · balance_after: Includes (i) 907,500 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; F3 · balance_after: (ii) 742,500 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; F4 · balance_after: (iii) 221,447 RSUs granted on February 25, 2021, of which 183,150 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 38,297 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; F5 · balance_after: (iv) 75,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 191,169 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| September 29, 2021 Filed Oct 2, 2021 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 742,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-033354 · form4.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037,616 F2 · shares: These shares represent RSUs that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022. F3 · balance_after: Includes (i) 907,500 Time-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and that will be settled into common stock upon vesting; (ii) 742,500 Milestone-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (2) and that will be settled into common stock upon vesting; (iii) 221,447 RSUs granted on February 25, 2021, of which 183,150 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 38,297 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; F4 · balance_after: (continued from footnote 3) (iv) 75,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 91,169 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| September 29, 2021 Filed Oct 2, 2021 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 907,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-033354 · form4.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,295,116 F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 458,700 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001193805-21-000293 · e620328_4-agrossman.xml · derivative · entry 4 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,700 Underlying: Common Stock · 458,700 shares Expires 2031-02-25 F5 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 221,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-21-000293 · e620328_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,545 F1 · shares: These shares represent restricted stock units ("RSUs"). Of these RSUs, 183,150 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 38,297 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 221,447 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 100,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (iii) 76,098 shares of common stock owned by the reporting person. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 12:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 4,000 | $2.24 | $8,959.60 |
DisclosureSEC source: 0001193805-20-001128 · e619921_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,098 F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 12:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 1,000 | $2.97 | $2,970.00 |
DisclosureSEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 4 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,098 F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 12:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 2,000 | $3.04 | $6,080.00 |
DisclosureSEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 3 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,098 F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 12:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 2,990 | $3.07 | $9,179.30 |
DisclosureSEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,098 F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 12:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 10 | $3.06 | $30.60 |
DisclosureSEC source: 0001193805-20-001005 · e619856_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,108 F1 · balance_after: Includes 100,000 restricted stock units granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:08 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 325,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001193805-20-000287 · e619421_4-agrossman.xml · derivative · entry 4 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2030-02-28 F5 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:08 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000287 · e619421_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,098 F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 100,000 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 66,098 shares of common stock owned by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 15:11 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 57,143 | $3.50 | $200,000.50 |
DisclosureSEC source: 0001193805-20-000127 · e619338_4-agrossman.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 878,444 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 15:11 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 28,571 | $3.50 | $99,998.50 |
DisclosureSEC source: 0001193805-20-000127 · e619338_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,098 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| May 17, 2019 Filed May 21, 2019 11:11 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0001193805-19-000520 · e618479_4-agrossman.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 821,301 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| May 17, 2019 Filed May 21, 2019 11:11 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 5,000 | $4.00 | $20,000.00 |
DisclosureSEC source: 0001193805-19-000520 · e618479_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,527 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001193805-19-000090 · e618164_4-agrossman.xml · derivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:09 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 52,301 | $4.78 | $249,998.78 |
DisclosureSEC source: 0001193805-18-000820 · e618086_4-agrossman.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 796,301 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:09 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 20,921 | $4.78 | $100,002.38 |
DisclosureSEC source: 0001193805-18-000820 · e618086_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,527 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001193805-18-000188 · e617682_4-agrossman.xml · derivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:46 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 485,000 | $2.15 | $1,042,750.00 |
DisclosureSEC source: 0001193805-17-003451 · e617469_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 744,000 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:14 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 42,021 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · derivative · entry 5 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,021 shares Expires 2017-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on July 16, 2007 (the "First Anniversary Date"), and the remaining seventy-five percent (75%) of the shares subject to the option vested in equal monthly installments over the three (3) year period following the First Anniversary Date. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:14 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 34,126 | $3.30 | $112,615.80 |
DisclosureSEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,606 Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:14 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 42,021 | $2.68 | $112,616.28 |
DisclosureSEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:03 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 583,224 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001059 · e616266_4-agrossman.xml · derivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,224 Underlying: Common Stock · 583,224 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.